Smith & Nephew
Smith & Nephew is an industry leader in each of our three main Global Business Units - Orthopaedic Reconstruction and Trauma, Endoscopy and Advanced Wound Management. These businesses jointly offer over 1,000 product ranges.
Our global infrastructure continues to expand each year. We currently operate in 32 countries and generate annual sales of $3.4 billion. Substantial investment in our products and intensive research and development means that we are always ahead. Figures from last year show that we stand at number one as the leading company in Arthroscopy. We are the second largest organisation in Advanced Wound Management and number three in Trauma and Clinical Therapies. We are also positioned at number four in reconstruction.
Smith & Nephew has a track record of bringing innovative new products to market that provide better clinical outcomes for patients and save costs for healthcare providers. This is the primary focus of our fourth business unit, Biologics.
Key People/Management at Smith & Nephew
Olivier Bohuon
Graham Baker
John W. Campo
Helen Maye
Philippe Mazas
Smith & Nephew Office Locations
Smith & Nephew Financials and Metrics
Smith & Nephew Revenue
| GBP | |
|---|---|
Revenue (FY, 2017) | 3.5 b |
Gross profit (FY, 2017) | 2.6 b |
Gross profit margin (FY, 2017), % | 73.8% |
Net income (FY, 2017) | 556.8 m |
EBITDA (FY, 2017) | 993.8 m |
EBIT (FY, 2017) | 678 m |
Market capitalization (16-Aug-2018) | 212.5 m |
Closing stock price (16-Aug-2018) | 2.4 |
Cash (31-Dec-2017) | 122.7 m |
EV | 109.4 m |
- Source: Company Filings
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.1 b | 1 b | 1.1 b | 1.1 b | 1.1 b | 1.1 b | 1.1 b | 1.2 b | 1.2 b | 1.4 b | 1.4 b | 2 b | 2.9 b | 3.2 b | 3.6 b | 3.4 b | 3.5 b |
Revenue growth, % | 11% | 0% | 13% | ||||||||||||||
Cost of goods sold | 472.6 m | 446.1 m | 453.3 m | 479.6 m | 456.8 m | 350.2 m | 329.9 m | 345.1 m | 334.8 m | 361 m | 1.1 b | 600.7 m | 724.8 m | 797.5 m | 883.4 m | 923.3 m | 905.9 m |
Gross profit | 596.6 m | 602 m | 600.1 m | 640.3 m | 677.9 m | 731.5 m | 780 m | 833.8 m | 913.7 m | 1 b | 292 m | 1.4 b | 2.1 b | 2.4 b | 2.7 b | 2.5 b | 2.6 b |
- Source: Company Filings
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 80.5 m | 57.1 m | 49.9 m | 100.5 m | 24.6 m | 30 m | 22.5 m | 26 m | 32.6 m | 88 m | 177 m | 102.7 m | 90.3 m | 63.8 m | 92.8 m | 72.6 m | 122.7 m |
Accounts Receivable | 218.7 m | 219.9 m | 233.1 m | 241.8 m | 246.2 m | 224.4 m | 222.6 m | 246 m | 273.5 m | 323 m | 322 m | 468.3 m | 616.1 m | 664.3 m | 751.3 m | 717.2 m | 766.6 m |
Inventories | 229.8 m | 225.7 m | 242.4 m | 237.6 m | 228.2 m | 232.2 m | 229.5 m | 230.6 m | 284.9 m | 355 m | 316 m | 504 m | 662.8 m | 810.5 m | 940.6 m | 903 m | 946.6 m |
Current Assets | 564.5 m | 561.3 m | 570.9 m | 619.2 m | 530.6 m | 525.4 m | 532.7 m | 591.1 m | 679.3 m | 937 m | 840 m | 1.2 b | 1.5 b | 1.7 b | 1.9 b | 1.8 b | 2 b |
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 120.7 m | 113.7 m | 93.7 m | 104.8 m | 205.2 m | 129.6 m | 112.1 m | 148.1 m | 125.2 m | 170 m | 201 m | 191 m | 366.3 m | 343.8 m | 316.9 m | 569.1 m | 556.8 m |
Cash From Operating Activities | 189.3 m | 181.7 m | 161.9 m | 198.1 m | 204 m | 191.9 m | 209.3 m | 214.5 m | 226.6 m | 147 m | 190 m | 264.7 m | 571.3 m | 468.7 m | 796.1 m | 616.3 m | 791.2 m |
Dividends Paid | 66.5 m | 69 m | 69.2 m | 72.5 m | 456.9 m | 42.9 m | 44.6 m | 46.1 m | 47.8 m | 50 m | 49 m | 62.8 m | 157.5 m | 164 m | 202.5 m | 195.3 m | |
Cash From Financing Activities | 40.4 m | (19.7 m) | 158.7 m | 17.8 m | 94.8 m | (93.1 m) | (16.9 m) | (22 m) | (196 m) | 209.7 m | (328.1 m) | 691.8 m | (431.3 m) | (384 m) | (315 m) |
| GBP | Y, 2017 |
|---|---|
EV/EBITDA | 0.1 x |
EV/EBIT | 0.2 x |
EV/CFO | 0.1 x |
Revenue/Employee | 228.4 k |
Financial Leverage | 1.7 x |
Smith & Nephew Operating Metrics
| FY, 2016 | |
|---|---|
Training Provided, no. of people | 90 k |
Smith & Nephew Revenue Breakdown
Smith & Nephew revenue breakdown by business segment: 12.9% from Sports Medicine Joint Repair , 13.9% from Arthroscopic Enabling Technologies , 9.9% from Trauma & Extremities, 19.8% from Knee Implants, 12.9% from Hip Implants, 14.9% from Advanced Wound Care, 6.9% from Advanced Wound Bioactives and 8.9% from Other
Smith & Nephew Online and Social Media Presence
3.4k Twitter followers
Smith & Nephew has 3.4k Twitter Followers. The number of followers has increased 1.8% month over month and increased 8% quarter over quarter
7.19k Facebook likes
Smith & Nephew has 7.19k Facebook Likes. The number of likes has increased 1.6% month over month and increased 9.2% quarter over quarter